The Impact of Confounders on Symptom-Endoscopic Discordances in Crohn's Disease

被引:2
|
作者
Rajan, Anjana [1 ]
Pan, Yushan [1 ]
Mahtani, Prerna [1 ]
Niec, Rachel [1 ]
Longman, Randy [1 ]
Gerber, Juliette [1 ]
Lukin, Dana [1 ]
Scherl, Ellen [1 ]
Battat, Robert [1 ,2 ,3 ]
机构
[1] Weill Cornell Med, Div Gastroenterol & Hepatol, New York Presbyterian Hosp, New York, NY USA
[2] Ctr Hosp Univ Montreal, Ctr Clin & Translat Res Inflammatory Bowel Dis, Montreal, PQ, Canada
[3] Ctr Hosp Univ Montreal, 900 St Denis St,R08 430, Montreal, PQ H2X 0A9, Canada
关键词
Crohn's disease; bile acid diarrhea; small intestinal bacterial overgrowth; inflammatory bowel disease; disease assessment; REPORTED OUTCOME MEASURES; BILE-ACID DIARRHEA; SERUM C4; RECURRENCE; DIAGNOSIS;
D O I
10.1093/crocol/otad017
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Discordances between clinical and endoscopic Crohn's disease (CD) activity indices negatively impact the utility of clinic visits and efficacy assessments in clinical trials. Bile acid diarrhea (BAD) and small intestinal bacterial overgrowth (SIBO) mimic CD symptoms. This study quantified the impact of BAD and SIBO on the relationship between clinical and endoscopic disease activity indices. Methods CD patients with 7 alpha-hydroxy-4-cholesten-3-one (7C4) serum measurements and/or SIBO breath tests and matched clinical and endoscopic scores were included. Clinical remission (stool frequency [SF] <= 1 and abdominal pain score <= 1) rates were compared between those with and without (1) endoscopic remission, (2) BAD (7C4 > 55 ng/mL), and (3) SIBO. Results Of 295 CD patients, 219 had SIBO testing and 87 had 7C4 testing. Patients with elevated 7C4 had lower proportions with clinical remission (14% vs 40%, P = .007) and SF <= 1 (14% vs 42%, P = .004) compared to those with normal 7C4. In patients with normal 7C4, higher rates of clinical remission (65% vs 27%, P = .01) and SF <= 1 (71% vs 27%, P = .003) existed in patients with endoscopic remission compared to those without endoscopic remission. Conversely, among the entire 295 patient cohorts, nearly identical clinical remission rates existed between those with and without endoscopic remission (25% vs 24%, P = .8), and the Crohn's Disease Patient-Reported Outcome-2 score was not accurate for predicting endoscopic remission (Area Under the Curve (AUC): 0.48; 95% CI, 0.42-0.55). SIBO status did not impact clinical remission rates (P = 1.0). Conclusions BAD, but not SIBO, contributed to symptom scores. A relationship between endoscopic inflammation and clinical remission rates only existed in patients without 7C4 elevations. Lay Summary In Crohn's disease patients, symptom-based clinical activity was not associated with endoscopic inflammation. Absence of bile acid diarrhea was associated with a reconciled relationship between endoscopy and symptoms. Small intestinal bacterial overgrowth was not associated with symptomatic remission rates or symptom-endoscopic discordances.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Endoscopic Prediction of Crohn's Disease Postoperative Recurrence
    De Cruz, Peter
    Hamilton, Amy L.
    Burrell, Kathryn J.
    Gorelik, Alexandra
    Liew, Danny
    Kamm, Michael A.
    INFLAMMATORY BOWEL DISEASES, 2022, 28 (05) : 680 - 688
  • [32] Endoscopic Treatment of Enterocutaneous Fistulas in Crohn's Disease
    Yzet, Clara
    Brazier, Franck
    Sabbagh, Charles
    Le Mouel, Jean-Philippe
    Hakim, Sami
    Nguyen-Khac, Eric
    Fumery, Mathurin
    DISEASES OF THE COLON & RECTUM, 2022, 65 (05) : 721 - 726
  • [33] Endoscopic and Mucosal Healing in Crohn's Disease with Azathioprine
    Nadir, Isilay
    Kafadar, Mehmet Tolga
    Kasapoglu, Benan
    JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, 2016, 7
  • [34] Update of endoscopic management of Crohn's disease strictures
    Pokala, Akshay
    Shen, Bo
    INTESTINAL RESEARCH, 2020, 18 (01) : 1 - 10
  • [35] Ileal Crohn's disease: MRI with endoscopic correlation
    Gallego, Jose C.
    Echarri, Ana I.
    Porta, Ana
    Ollero, Virginia
    EUROPEAN JOURNAL OF RADIOLOGY, 2011, 80 (02) : E8 - E12
  • [36] Endoscopic Monitoring of Infliximab Therapy in Crohn's Disease
    af Bjorkesten, Clas-Goran
    Nieminen, Urpo
    Turunen, Ulla
    Arkkila, Perttu E.
    Sipponen, Taina
    Farkkila, Martti A.
    INFLAMMATORY BOWEL DISEASES, 2011, 17 (04) : 947 - 953
  • [37] Systematic review: endoscopic dilatation in Crohn's disease
    Hassan, C.
    Zullo, A.
    De Francesco, V.
    Ierardi, E.
    Giustini, M.
    Pitidis, A.
    Taggi, F.
    Winn, S.
    Morini, S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (11-12) : 1457 - 1464
  • [38] Endoscopic and Medical Management of Fibrostenotic Crohn's Disease
    Thienpont, Clara
    Van Assche, Gert
    DIGESTIVE DISEASES, 2014, 32 : 35 - 38
  • [39] The impact of genetics on Crohn's Disease
    Del Gaudio, A
    Panettiere, P
    Marchetti, L
    Accorsi, D
    Fuzzi, N
    HEPATO-GASTROENTEROLOGY, 1999, 46 (26) : 784 - 789
  • [40] Endoscopic dilations of intestinal stenosis in Crohn's disease
    Badre, W.
    Bahlaoui, O.
    El Rhaoussi, P. Z.
    Tahiri, M.
    Haddad, E.
    Hliwa, X.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S499 - S501